预知治疗获得FDA批准, 进行其新型癌症药物PTX-100的第二阶段试验. Prescient Therapeutics gains FDA approval for Phase 2 trials of its new cancer drug, PTX-100.

Prescient Therapeutics 已获得 FDA 批准，开始其 PTX-100 药物的 2 期试验，该药物旨在治疗晚期实体瘤。 Prescient Therapeutics has received FDA approval to begin Phase 2 trials for its PTX-100 drug, which aims to treat advanced solid tumors. 这一批准是在成功进行第一阶段试验之后批准的,标志着药物研制工作取得显著进展。 This approval follows successful Phase 1 trials and marks a significant advancement in the drug's development. PTX-100是一种新型的双双PI3K/mtor抑制剂,将结合其他癌症疗法测试其安全、可耐性和有效性。 PTX-100 is a novel dual PI3K/mTOR inhibitor that will be tested for safety, tolerability, and effectiveness in combination with other cancer therapies.